154447-35-5 | 2-(Morpholin-4-yl)benzo[h]chromen-4-one

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$32.00	$22.00
5mg	95%	in stock	$105.00	$73.00
10mg	95%	in stock	$196.00	$137.00
25mg	95%	in stock	$458.00	$321.00
50mg	95%	in stock	$813.00	$569.00

Description

• Catalog Number: AF00475
• Chemical Name: 2-(Morpholin-4-yl)benzo[h]chromen-4-one
• CAS Number: 154447-35-5
• Molecular Formula: C17H15NO3
• Molecular Weight: 281.3059
• MDL Number: MFCD06798345
• SMILES: O=c1cc(oc2c1ccc1c2cccc1)N1CCOCC1

Computed Properties

• Complexity: 441
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 1
• XLogP3: 2.8

Literature

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Clioquinol induces DNA double-strand breaks, activation of ATM, and subsequent activation of p53 signaling.

  Toxicology 20120904

• Regulation of DNA damage response and cell cycle in radiation-resistant HL60 myeloid leukemia cells.

  Oncology reports 20120701

• Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

  Investigational new drugs 20120601

• DNA double-strand breaks induced by cavitational mechanical effects of ultrasound in cancer cell lines.

  PloS one 20120101

• Identification of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel target of bisphenol A.

  PloS one 20120101

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.

  Bioorganic & medicinal chemistry 20110701

• A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia.

  Journal of cell science 20110601

• Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

  Journal of medicinal chemistry 20110414

• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

  Nature chemical biology 20110413

• Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.

  PloS one 20110101

• DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.

  Journal of medicinal chemistry 20101223

• DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.

  Experimental oncology 20101201

• DNA-PK promotes the survival of young neurons in the embryonic mouse retina.

  Cell death and differentiation 20101101

• Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}.

  Cancer research 20101101

• Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs.

  Aging 20101001

• Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.

  Science translational medicine 20100908

• DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells.

  Free radical biology & medicine 20100515

• Suppression of DNA-PKcs enhances FGF-2 dependent human endothelial cell proliferation via negative regulation of Akt.

  Cellular signalling 20100101

• ATM is the predominant kinase involved in the phosphorylation of histone H2AX after heating.

  Journal of radiation research 20100101

• Impaired NHEJ function in multiple myeloma.

  Mutation research 20090115

• Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro.

  The Journal of biological chemistry 20080418

• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

  Proceedings of the National Academy of Sciences of the United States of America 20071218

• Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.

  The Journal of pharmacology and experimental therapeutics 20070601

• Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma a549 cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20060501

• DNA end joining activity is reduced in Alzheimer's disease.

  Neurobiology of aging 20060401

• Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.

  Nucleic acids research 20060101

• Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.

  Journal of medicinal chemistry 20051201

• Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

  British journal of cancer 20051031

• Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.

  Blood 20050615

• Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.

  Journal of medicinal chemistry 20050127

• Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.

  Bioorganic & medicinal chemistry letters 20041220

• Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.

  Oncogene 20040923

• A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

  Blood 20040615

• 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK).

  Bioorganic & medicinal chemistry letters 20030915

• Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.

  Cancer research 20030915

• LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.

  Bioorganic & medicinal chemistry letters 20010409

• The DNA-dependent protein kinase.

  Genes & development 19990415

• Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19970701

• Differential implications of the oncogene-tumor suppressor gene complex in the geneses of 19 human neoplasias. Evidence in support of the steroid carcinogenesis hypothesis.

  Anticancer research 19970101